---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000840"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-01-18T23:59:59+00:00"
generated_at: "2026-06-20T14:04:16.834534+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aeglea BioTherapeutics receives Nasdaq minimum bid price deficiency notice; 180-day cure period to July 12, 2023

## Summary
- Received Nasdaq notice on Jan 13, 2023 for closing bid price below $1.00 for 30 consecutive trading days.
- Must regain compliance by July 12, 2023 with bid price >= $1.00 for at least 10 consecutive days.
- If not compliant by July 12, may transfer to Nasdaq Capital Market for an additional 180-day cure period.
- No immediate effect on listing; company intends to monitor bid price and consider options.
- Failure to regain compliance could result in delisting subject to appeal rights.

## SEC filing metadata
- accession: 0000950170-23-000840
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-01-18T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000095017023000840/0000950170-23-000840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000095017023000840/agle-20230113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000840
- JSON: https://secwatch.observer/filing/0000950170-23-000840.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000840.txt

## Key facts
- Listing & Compliance Notices
  Spyre Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: January 13, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000095017023000840/0000950170-23-000840-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.